The global inflammatory bowel disease treatment market size is expected to reach USD 30.80 billion by 2030, according to a new study by Polaris Market Research. The report “Inflammatory Bowel Disease Treatment Market Share, Size, Trends, Industry Analysis Report, By Disease indication; By Drug Class; By Route of Administration; By Distribution Channel; By Region; Segment Forecast, 2022 – 2030” gives a detailed insight into current market dynamics and provides analysis on future market growth.
The industry for enhanced diagnostic and therapy for inflammatory bowel disease is growing as a result of rising cases of IBD in various regions. The frequency of ulcerative colitis and Crohn’s disease is on the rise as a result of a number of variables, such as genetic predisposition, environmental triggers, and immune system disruption.
Have Questions? Request a sample or make an Inquiry before buying this report by clicking the link below: https://www.polarismarketresearch.com/industry-analysis/global-inflammatory-bowel-disease-ibd-market/request-for-sample
Most people with Crohn’s disease or ulcerative colitis have a family history of the disorder. Each year, 70,000 new cases of IBD are identified, and up to 80,000 youngsters may develop ulcerative colitis or Crohn’s disease (CD) (UC). According to Hammer et al., IBD is thought to affect 2.5 to 3 million people in Europe or around 0.3% of the overall population. As per British medical journals, IBD could affect up to 240 000 people in the UK.
Increased disease detection rates and adequate reimbursement regulations in industrialized countries aid industry expansion as early disease diagnosis becomes increasingly crucial. As a result, more patients are obtaining treatment for IBD, which has increased demand for drugs, including toll-like receptor agonists, TNF inhibitors, IL inhibitors, JAK inhibitors, and others that are used to treat the condition.
A larger disease burden of IBD, significant improvements in our understanding of disease pathophysiology, and the development of improved diagnostic and therapeutic drugs are among additional variables that contribute to increased diagnosis rates. In addition to the previously mentioned improvements in access to healthcare systems, better diagnostic techniques for detecting UC early in the illness course, and more knowledge among physicians, patients, and healthcare professionals.
Inflammatory Bowel Disease Treatment Market Report Highlights
- In 2021, Crohn’s disease dominated the IBD market. It is expected that the segment will remain dominant during the forecast period.
- The injectable category dominated the market for the treatment of inflammatory bowel disease in 2021 with a revenue share. The segment’s dominance is due to the great efficacy of injectable drugs.
- The hospital pharmacy industry dominated the market for the treatment of inflammatory bowel disease in 2021, accounting for the largest revenue share. The sector is predicted to dominate the market during the forecasted period.
- The industry players with global presence includes AbbVie, Biogen, Johnson & Johnson, Amgen, UCB S.A., Novartis AG, Takeda Pharmaceutical Company Limited, Bausch Health, Bristol-Myers Squibb Company, Gilead sciences, Merck, Pfizer, Lilly, and Celltrion.
Polaris Market Research has segmented the Inflammatory Bowel Disease Treatment market report based on drug class, route of administration, distribution channel, and region:
Inflammatory Bowel Disease Treatment, Type Outlook (Revenue, USD Million, 2018 – 2030)
- Crohn’s Disease
- Ulcerative Colitis
Inflammatory Bowel Disease Treatment, Drug Class Outlook (Revenue, USD Million, 2018 – 2030)
- Amino salicylates
- TNF inhibitors
- IL inhibitors
- JAK inhibitors
Inflammatory Bowel Disease Treatment, Route of Administration Outlook (Revenue, USD Million, 2018 – 2030)
Inflammatory Bowel Disease Treatment, Distribution Channel Outlook (Revenue, USD Million, 2018 – 2030)
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
Inflammatory Bowel Disease Treatment, Regional Outlook (Revenue, USD Million, 2018 – 2030)
- North America
- Asia Pacific
- South Korea
- Latin America
- Middle East & Africa
- Saudi Arabia
- South Africa